Risperidone and aripiprazole are metabolized by the cytochrome P450 2D6 (CYP2D6). Individuals can be categorized as ultrarapid, normal, intermediate, or poor metabolizers (UM, NM, IM and PM, respectively). Greater odds of switching from risperidone (but not from aripiprazole) were previously reported among PM and UM. Importantly, the duration of treatment up to switching was unknown.
No takes yet. Share an insight, caveat, or question.
Eap et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: